APH vs NRIX · P/E 40, rev $23.09B vs rev $54.5M
Amphenol Corporation (APH) versus Nurix Therapeutics Inc (NRIX) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
APH currently screens at market cap $170.77B and trailing P/E 39.9. NRIX currently screens at market cap $1.77B.
Not investment advice. Open the APH and NRIX stock pages for the full models.
Not investment advice.